Associate
Jameson contributes to various litigation stages and is involved with pre-litigation analyses, discovery, and drafting expert reports. He also prepares and prosecutes patent applications before the U.S. Patent and Trademark Office (USPTO) and in international jurisdictions for a wide range of biotechnology and pharmaceutical companies. His practice includes developing landscape and freedom-to-operate analyses as well as providing validity and patentability opinions.
Jameson possesses technical experience with a broad array of life sciences technologies, including antibodies and antibody-drug conjugates, cancer immunotherapies, diagnostic markers and assays, drug formulations, gene editing, next-generation sequencing, nutraceuticals, peptides, and small molecule drugs.
Before attending law school, Jameson completed his doctoral studies in molecular and cellular biology at Arizona State University and conducted research at the University of Arizona College of Medicine-Phoenix. His research investigated the function of a recently identified cytokine in the immune response to genital herpes and other maladies affecting the female reproductive tract. During his undergraduate studies, Jameson researched the mechanisms for sensing and responding to environmental phosphate in E. coli.
Jameson is committed to pro bono practice. He works with military veterans pursuing appeals for service-connected disability benefits and other parties before the Merit Systems Protection Board.
Event
Patent Inventorship: Best Practices for Determination and Correction Patent Inventorship: Best Practices for Determination and Correction
May 7, 2024
Webinar
Articles
Trending at the PTAB: Changes to Director Review, Hearings Trending at the PTAB: Changes to Director Review, Hearings
October 4, 2023
Law360At the PTAB Blog
Statements and Arguments in IPR Proceedings Challenging Unrelated Patents May Impact a District Court’s Claim Construction Analysis Statements and Arguments in IPR Proceedings Challenging Unrelated Patents May Impact a District Court’s Claim Construction Analysis
April 20, 2023
At the PTAB Blog
The Board Denied Institution Due to Petitioner’s Admission that Its Proposed Structure for a Means-Plus Function Limitation Was Incorrect The Board Denied Institution Due to Petitioner’s Admission that Its Proposed Structure for a Means-Plus Function Limitation Was Incorrect
April 11, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.